CURRENT ORAL MUSCLE RELAXANTS IN THE COMBINATION THERAPY OF PAIN SYNDROMES

Download full text PDF
Issue: 
3
Year: 
2017

A. Vasilyev, Candidate of Medical Sciences Central State Medical Academy, Department for Presidential Affairs of the Russian Federation, Moscow

The paper considers the treatment of central spasticity and myofascial pain syndromes with oral muscle relaxants and another therapy. It presents a number of recommendations for the management of patients of this gpoup. The data available in the literature data on spasticity treatment with oral muscle relaxants are given.
Keywords: 
neurology
spasticity
myofascial pain syndrome
treatment
baclofen

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Pandyan A., Gregoric M., Barnes M. et al. Spasticity: clinical perceptions, 367 neurological realities and meaningful measurement // Disabil. Rehabil. – 2005; 27: 2–6.
  2. Bhadra N. Neuroprostheses for spasticity control. In: Kilgore K, editor. Implantable neuroprostheses for restoring function / Cambridge: Elsevier, 2015; 331.
  3. Ertzgaard P., Anhammer M., Forsmark A. Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap // Acta Neurol. Scand. – 2017; 135 (3): 366–72.
  4. Brainin M., Norrving B., Sunnerhagen K. et al. Poststroke chronic disease management: towards improved identification and interventions for poststroke spasticity-related complications // Int. J. Stroke. – 2011; 6: 42–6.
  5. Ryu J., Lee J., Lee S. et al. Factors predictive of spasticity and their effects on motor recovery and functional outcomes in stroke patients // Top Stroke Rehabil. – 2010; 17: 380–8.
  6. Jensen R., Olesen J. et al. Tension-type headache: an update on mechanisms and treatment // Cur. Opin. Neurol. – 2000; 13 (3): 285–9.
  7. Isajkin A.I., Kuznetsov I.V., Kavelina A.V. i dr. Fasetochnyj sindrom: prichiny vozniknovenija, klinika, diagnostika i lechenie // Consilium Medicum. (Pril.). – 2016; 2: 53–61.
  8. Deyo R., Weinstein J. Low Back Pain // N. Engl. J. Med. – 2001; 344 (5): 363–70.
  9. Henschke N., Maher C., Refshauge K. et al. Prevalence of and screening for serious spinal pathology in patient presenting to primary care settings with acute low back pain // Arthritis Rheum. – 2009; 60 (10): 3072–80. Doi: 10.1002/art.24853
  10. Manchikanti L., Standiford Helm, Vijay Singh et al. Algorithmic Approach for Clinical Management of Chronic Spinal Pain // Pain Physician. – 2009; 12: 225–64.
  11. De Palma M., Ketchum J., Saullo T. What is the source of chronic low back pain and does age play a role? // Pain Med. – 2011; 12 (2): 224–33.
  12. Vasil'ev A.S., Vasil'eva V.V. Mezhdistsiplinarnye aspekty vedenija patsientov s sindromom torakalgii // Kremlevskaja meditsina. Klinicheskij vestnik. – 2013; 3: 62–5.
  13. Parfenov V.A., Batysheva T.T. Boli v spine: boleznennyj myshechnyj spazm i ego lechenie miorelaksantami // Lechaschij vrach. – 2013; 4: 16–8.
  14. Drug Monograph. Baclofen https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-56
  15. Katz P., Gerson L., Vela M. Guidelines for the diagnosis and management of gastroesophageal reflux disease // Am. J. Gastroenterol. – 2013; 108: 308–28.
  16. Fromm G., Terrence C., Chattha A. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up // Ann. Neurol. – 1984; 15: 240–4.
  17. Vasil'eva V.V., Shmyrev V.I., Vasil'ev A.S. Myshechnotonicheskij disbalans u detej pervyh nedel' i mesjatsev zhizni // Vrach. – 2010; 1: 8–10.
  18. Duncan G., Shahani B., Young R. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study // Neurology. – 1976; 26: 441–6.
  19. Feldman R., Kelly-Hayes M., Conomy J. et al. Baclofen for spasticity in multiple sclerosis.Double-blind crossover and three-year study // Neurology. – 1978; 28: 1094–8.
  20. Sawa G., Paty D. The use of baclofen in treatment of spasticity in multiple sclerosis // Can. J. Neurol. Sci. – 1979; 6: 351–4.
  21. Milla P., Jackson A. A controlled trial of baclofen in children with cerebral palsy // J. Int. Med. Res. – 1977; 5: 398–404.
  22. Medaer R., Hellebuyk H., Van den Brande E. et al. Treatment of spasticity due to stroke. A double-blind, cross-over trial comparing baclofen with placebo // Acta Ther. – 1991; 17: 323–31.
  23. Smolenski Ch., Muff S., Smolenski-Kautz S. A double-blind comparative trial of a new muscle relaxant, tizanidine (DS 103–282), and baclofen in the treatment of chronic spasticity in multiple sclerosis // Curr. Med. Res. Opin. – 1981; 7: 374–83.
  24. Stien R., Nordal H., Oftedal S. et al. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine* compared with baclofen // Acta Neurol. Scand. – 1987; 75: 190–4.
  25. Medici M., Pebet M., Ciblis D. A double-blind, long-term study of tizanidine (‘Sirdalud’)in spasticity due to cerebrovascular lesions // Curr. Med. Res. Opin. – 1989; 11: 398–405.
  26. Hoogstraten M., van der Ploeg R., vd Burg W. et al. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients // Acta Neurol. Scand. – 1988; 77: 224–30.
  27. Bresolin N., Zucca C., Pecori A. Efficacy and tolerability of eperisone and baclofen in spastic palsy: A double-blind randomized trial // Adv. Ther. – 2009; 26: 563–73.
  28. Baclofen Tablet package insert. Sellersville, PA: Teva Pharmaceuticals USA, 2010 Jun.
  29. Lioresal (baclofen) injection package insert. Minneapolis, MN: Medtronic, Inc., 2016 Sep.